MTOR inhibitor-based combination therapies for pancreatic cancer
BRITISH JOURNAL OF CANCER, cilt.118, sa.3, ss.366-377, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 118 Sayı: 3
- Basım Tarihi: 2018
- Doi Numarası: 10.1038/bjc.2017.421
- Dergi Adı: BRITISH JOURNAL OF CANCER
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.366-377
- Anahtar Kelimeler: MTOR, pancreatic cancer, therapeutic resistance, IN-VIVO, DUCTAL ADENOCARCINOMAS, FEEDBACK ACTIVATION, PRECLINICAL MODELS, CELL PLASTICITY, ONCOGENIC KRAS, LUNG-CANCER, TUMORIGENESIS, RESISTANCE, EGFR
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır
Özet
Background: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs further clarification.